1. Home
  2. NERV vs TNXP Comparison

NERV vs TNXP Comparison

Compare NERV & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.11

Market Cap

210.1M

Sector

Health Care

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$9.92

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NERV
TNXP
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.1M
199.7M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
NERV
TNXP
Price
$4.11
$9.92
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.50
N/A
AVG Volume (30 Days)
358.2K
544.8K
Earning Date
05-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
$41,175,600.00
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$1.76
$10.03
52 Week High
$12.46
$69.65

Technical Indicators

Market Signals
Indicator
NERV
TNXP
Relative Strength Index (RSI) 40.62 35.99
Support Level $3.80 N/A
Resistance Level $4.59 $13.18
Average True Range (ATR) 0.38 0.93
MACD -0.01 -0.22
Stochastic Oscillator 18.81 1.20

Price Performance

Historical Comparison
NERV
TNXP

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: